| Name | Title | Contact Details |
|---|
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
Dainippon Sumitomo Pharma America Holdings is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sequella is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ChemBridge Corporation is a privately held US company founded in Chicago in 1993 and relocated to San Diego in 1997. ChemBridge has European offices in the UK, a marketing agency in Japan, and operates a large, state-of-the-art offshore chemistry
URL Pharma/United Research Laboratories is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.